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indirect costs (versus 0) and the probability that patients with positive costs spent 
more than a4000 (versus less than a4000). RESULTS: Out of the 3494 questionnaires 
mailed 1189 (34.0%) were returned and fully completed. The mean age of respondents 
was 53.1 years (SD 8.6); 85.4% were women and the mean RA duration was 14.7 
years (SD 9.7). At the time of the survey, 49.9% of respondents were employed, 32.7% 
declared being on RA work disability perceiving pension invalidity. A total of 45.3% 
of employed patients had at least one sick leave over the past 6 months, with on 
average a cumulative duration of 11.6 days over. The average annual estimated indi-
rect cost was a3210 (74.4% RA-related work disability and 25.6% due to RA sick 
leaves). The three main risk factors associated with higher costs were: failure of at 
least one biotherapy (Odds Ratio-OR  4.8), RA poor functional status (severe HAQ 
versus mild HAQ, OR  3.8) and on-going treatment (disease-modifying antirheumatic 
drugs versus etanercept, OR  3.5). A high level of education is protective (OR  0.6). 
CONCLUSIONS: Pursuing preservation of functional status by treating patients 
earlier before irreversible joint damages could both improve patients’ work conditions 
and lead to potential savings for the Health Insurance.
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OBJECTIVES: Rituximab and inﬂiximab are biologic disease modifying anti-
 rheumatic drugs (DMARDS) used to treat rheumatoid arthritis (RA). Rituximab is 
re-dosed when signs and symptoms return, but inﬂiximab has ﬁxed dosing intervals. 
This 3-centre observational study was to determine the secondary care resource and 
patient time implications of this difference. METHODS: Medical records of 44 
patients with RA, treated with inﬂiximab (n  26) or at least 2 courses of rituximab 
(n  18) were reviewed retrospectively to determine mean time between end of 1st 
rituximab course and start of the 2nd, and numbers of visits and investigations for 
both drugs. Staff and patient time required for drug administration was measured 
prospectively by direct observation of 25 patients receiving inﬂiximab (n  13) or 
rituximab (n  12). RESULTS: Mean time between 1st and 2nd courses of rituximab 
was 43 weeks (range 15–84). During this time a mean of 6.9 (range 4–8) inﬂiximab 
infusions was administered. Rituximab-treated patients required 2 visits for drug 
administration during this time, vs. inﬂiximab 6.9 visits. Each visit required a mean 
of 87.2 minutes of staff time for rituximab patients vs. 46.0 minutes for inﬂiximab. 
Total staff time per patient over 43 weeks was 2.9 hours for rituximab vs. 5.3 hours 
for inﬂiximab. Mean total patient time in the unit per 43 weeks was 14.1 hours for 
rituximab vs. 25.3 hours for inﬂiximab. CONCLUSIONS: Although rituximab 
requires almost twice as much staff time per visit for its administration as inﬂiximab, 
it is administered less often so staff time required over a whole course is less for 
rituximab than inﬂiximab. An even greater difference was seen for patient time spent 
on the unit for drug administration. This study demonstrates beneﬁts from rituximab 
in terms of patient convenience and staff efﬁciency, which can inform NHS planning 
of service delivery and quality standards for patients with RA.
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OBJECTIVES: Anaemia is prevalent among old individuals. Iron deﬁciency due to 
chronic gastrointestinal loss is a frequent cause. Non-steroidal anti-inﬂammatory 
drugs (NSAIDs) are a major cause of bleeding among osteoarthritis (OA) patients. 
Analysis of Hospital Events Meaning IAtrogenicity (ANHEMIA) study aims at assess-
ing the demographic characteristics of anaemia in french OA patients and its impact 
on hospital length of stay (LOS). METHODS: Programme de Médicalisation des Sys-
tèmes d’Information (PMSI) database covers french hospital activity and is used by 
Health Authorities as resources use indicators for allocating and forecasting medical 
budget. Its Use to assess the epidemiological and economic burden of illness is recom-
mended. Cross-linkage through the ICD-10 diagnosis codes allowed the identiﬁcation 
of hospital stays with a main diagnosis of osteoarthritis (OA) and Among these, 
2 subpopulations according to the existence or absence of iron-deﬁciency anaemia 
(AN or AN-). ICD-10 diagnosis cancers were excluded. Four groups were established 
for analysis: OAAN-, OAAN in either private or public hospitals (PrH, PuH). 
RESULTS: All the groups analysis showed a higher percentage of women (p  0.001): 
2 out of every 3 patients. In PuH, mean age of OAAN patients was 73.5 years vs. 
65.3 for OAAN- patients, in PrH: 69.0 years (OAAN) vs. 58.3 (OAAN-). 
Overall, OAAN patients were signiﬁcantly older than 65 compared to OAAN- 
patients: 88.1% vs. 68.7% (p  0.001) both in PrH or PuH. Compared to OAAN- 
patients, OAAN patients had a longer LOS: 2.58 days in PuH, 2.49 days in PrH 
for matched DRG. The increase in LOS was accountable for substantial extra costs: 
a791,504 for PuH and a760,080 for PrH for the year 2006. CONCLUSIONS: 
Anaemia, is an important driver for extra-costs in hospitalized OA population. Since 
this population is likely to grow in the forthcoming years, every effort to reduce its 
incidence of anaemia should be considered.
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OBJECTIVES: Minimal Access Spinal Technologies (MAST TM) potentially allows 
surgeons to treat back pain and disability with the least amount of interruption while 
achieving the same surgical objectives as open surgeries. This single center resource 
use utilization study was designed to assess difference between MAST TM and open 
surgery in hospital length of stay and its associated costs from a hospital perspective. 
METHODS: This study aims at comparing the average length of hospital stay (LOS) 
of patients treated with MAST TM in the Foch hospital and the average National 
LOS of patients treated with open surgery. All patient operated with MASTTM in 
2007 in Foch hospital were retrospectively analyzed and were indirectly compared 
with patients from the National French DRG data base called PMSI. MASTTM and 
open surgery patients were matched on procedure code. Cost per hospital stay has 
been assessed with the French National Cost Study (ENC). RESULTS: In 2007, Foch 
hospital performed 250 MAST surgeries. The two main procedures were posterior 
lumbar arthrodesis (procedure code LFDA004/0; n  68) and removal of herniated 
disc (procedure code LFFA002/0; n  111). For posterior lumbar arthrodesis surgery, 
the average LOS in Foch Hospital was 5.9 days compared to 8.9 days in the national 
data base (34% decrease). For herniated disc surgery, the average LOS in Foch hospital 
was 3.4 days compared to 5.3 days in the national data base (36% decrease). In 2007, 
Foch hospital avoided 215 days of hospitalization with the MAST, representing 
between a133,000 and a141,000 (a320–a340 per day). CONCLUSIONS: By lowering 
morbidity and reducing recovery time, MAST TM reduces costs of hospital stays. The 
reduction of hospital days may off-set any additional device costs. Further prospective 
research should be considered to validate our ﬁndings; however this is one of the ﬁrst 
studies investigating systematically this subject.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcome Studies
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OBJECTIVES: To estimate the inﬂuence of non-compliance on the risk of fractures 
in German osteoporosis patients treated with oral bisphosphonate (oBP) therapy. 
METHODS: IMS® Disease Analyzer database was used; includes 11 million patients 
from ofﬁce-based physicians. Eligible osteoporosis patients (excluding malignant dis-
eases, any anticancer or cytostatic hormone prescription, Paget’s disease or AIDS) had 
data available q1-year before and after initiating oBP treatment (December 2004-
November 2007). Compliance was measured as Medical Possession Ratio (MPR; 
prescribed to assumed number of therapy units). MPR  80% assumed compliance. 
MPR was calculated for patients on therapy up to 2 years. Fractures were identiﬁed 
by ICD-10 codes; only fractures 3 months after initiating oBP were included. The 
inﬂuence of compliance on time to fracture was determined by Kaplan-Meier and Cox 
regression analyses. The model was adjusted for gender, age, prevalence of fractures 
1 year before index prescription, calcium/vitamin D co-prescription, continuation of 
the initial regimen after 6 months and after 1 year. RESULTS: A total of 4738 patients’ 
data were analyzed: 1365 (28.8%) with previous fractures. The total number of 
patients receiving oBP treatment was 177 (3.7%) daily, 4367 (92.2%) weekly and 
194 (4.1%) monthly. After 2 years, 14.5% (daily), 12.2% (weekly), and 9.7% 
(monthly) of patients experienced a fracture. The time to fracture was signiﬁcantly 
longer for compliant versus non-compliant patients (log rank test; p  0.013). Compli-
ance was associated with a 26% (95% CI 10–39%) decrease in the fracture rate versus 
non-compliance. Higher age (60 years) (44% increase; 95%CI 3–100%) and previ-
ous fractures (29% increase; 95%CI 5–57%) were associated with a signiﬁcantly 
higher risk of fractures. CONCLUSIONS: Patients receiving oBP therapy who are 
compliant have a decreased risk of fractures versus non-compliant patients. Older 
patients and those with fracture history are particularly at risk of fracture. These 
ﬁndings highlight the need to improve compliance to reduce the risk of osteoporosis-
associated fractures.
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OBJECTIVES: To examine the effect of medication choice between duloxetine and 
pregabalin on medication compliance outcomes as well as direct health care costs 
among patients with ﬁbromyalgia. METHODS: A retrospective cohort study design 
was used with a large US national commercial health care claims database over 
2005–2007. Fibromyalgia patients aged 18–64 who initiated (no pill coverage in the 
previous 90 days) duloxetine or pregabalin in 2006 were selected, with the ﬁrst initia-
tion date as the index date. All patients included had continuous enrollment in the 12 
